Evrys Bio: Funding, Investors & Team (Oct 2026)
Evrys Bio was founded on breakthrough discoveries made at Princeton University. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, Evrys Bio antivirals engage the cell’s intrinsic immunity to defend against infection. Evrys Bio’s vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug-resistance, and provide unique broad-spectrum treatment options. This will transform the practice of medicine by addressing the infectious disease condition holistically as opposed to targeting a specific virus-type.
Evrys Bio has raised $34.3M across 1 funding round on record, the most recent a Grant of $34.3M announced in Jul 2021.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Evrys Bio Company Profile and Key Stats
Latest funding round on record: Jul 2021.
Evrys Bio Funding Rounds
Evrys Bio Founders and Leadership Team
No contact details are on record for this team yet.
Evrys Bio Funding Compared to Other Biotechnology Startups
Evrys Bio's latest round of $34.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Evrys Bio in Biotechnology and Doylestown
Companies Similar to Evrys Bio
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Evrys Bio Funding FAQs
What does Evrys Bio do?
Evrys Bio was founded on breakthrough discoveries made at Princeton University. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, Evrys Bio antivirals engage the cell’s intrinsic immunity to defend against infection. Evrys Bio’s vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug-resistance, and provide unique broad-spectrum treatment options. This will transform the practice of medicine by addressing the infectious disease condition holistically as opposed to targeting a specific virus-type.
How much funding has Evrys Bio raised?
Evrys Bio has raised $34.3M across 1 round on record. The most recent is a Grant of $34.3M announced in Jul 2021.
When did Evrys Bio last raise funding?
Evrys Bio's most recent funding round on record is a Grant of $34.3M, announced in Jul 2021.
Who is the CEO of Evrys Bio?
Lillian Chiang is listed as CEO at Evrys Bio.
Where is Evrys Bio headquartered?
Evrys Bio is based in Doylestown, Pennsylvania, United States.
How many employees does Evrys Bio have?
Evrys Bio is in the 11-50 employee band.
How does Evrys Bio's funding compare to other Biotechnology startups?
Evrys Bio's latest round of $34.3M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Evrys Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Evrys Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.